SEC Form 4 filings for KOZARICH JOHN W,

Insider trading of John W Kozarich, a Director at LGND Ligand Pharmaceuticals Incorporated

Most recently John W Kozarich sold 2,500 shares worth $362,500.00 on 10 January 2018.

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2018-01-10 John W Kozarich
Director
Director Sale 2,500 $145.00 $362,500.00
2018-01-10
33,149 SEC insider form 4
2017-11-16 John W Kozarich
Director
Director Sale 5,000 $141.71 $708,550.00
2017-11-16
35,649 SEC insider form 4
2016-09-07 John W Kozarich
Director
Director Sale 1,000 $115.00 $115,000.00
2016-09-07
39,983 SEC insider form 4
2016-09-01 John W Kozarich
Director
Director Sale 1,666 $105.40 $175,596.40
2016-09-01
39,317 SEC insider form 4
2016-08-01 John W Kozarich
Director
Director Sale 1,000 $137.57 $137,570.00
2016-08-01
40,983 SEC insider form 4
2016-07-01 John W Kozarich
Director
Director Sale 1,000 $121.40 $121,400.00
2016-07-01
41,983 SEC insider form 4
2016-05-20 John W Kozarich
Director
Director Sale 1,000 $117.42 $117,420.00
2016-05-20
42,983 SEC insider form 4
2016-05-02 John W Kozarich
Director
Director Sale 1,000 $121.57 $121,570.00
2016-05-02
43,711 SEC insider form 4
Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The company??s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.

  • Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Boulevard, San Diego 92121, United States
  • ligand.com
  • 858-550-7500
Messenger